News | January 03, 2024
WuXi XDC partners with IntoCell to accelerate ADC discovery and development
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Development services for gene and cell therapies is planned to begin first in 2025
Lack of technology transfer stands out as a formidable barrier
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Subscribe To Our Newsletter & Stay Updated
